Logo
x

Search

Subscribe Now

Shanghai Henlius

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

  • September 2, 2024
Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

  • May 24, 2024
Accord BioPharma’s Hercessi (Biosimilar, Herceptin) Receives the US FDA Approval

Accord BioPharma’s Hercessi (Biosimilar, Herceptin) Receives the US FDA Approval

  • April 29, 2024
Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

  • April 8, 2024
Shanghai Henlius Reports P-III Placebo-Controlled Trial Results of HLX01 (biosimilar, rituximab) for Active Rheumatoid Arthritis

Shanghai Henlius Reports P-III Placebo-Controlled Trial Results of HLX01 (biosimilar, rituximab) for Active Rheumatoid Arthritis

  • October 10, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.